These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 7613558)

  • 41. Rapid and accurate prediction of degradant formation rates in pharmaceutical formulations using high-performance liquid chromatography-mass spectrometry.
    Darrington RT; Jiao J
    J Pharm Sci; 2004 Apr; 93(4):838-46. PubMed ID: 14999722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Applications of process analytical technology to crystallization processes.
    Yu LX; Lionberger RA; Raw AS; D'Costa R; Wu H; Hussain AS
    Adv Drug Deliv Rev; 2004 Feb; 56(3):349-69. PubMed ID: 14962586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of physicochemical properties in the estimation of skin permeability: in vitro data assessment by Partial Least-Squares Regression.
    Chauhan P; Shakya M
    SAR QSAR Environ Res; 2010 Jul; 21(5-6):481-94. PubMed ID: 20818583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimating shelf-life of drugs in solution.
    Newton DW; Miller KW
    Am J Hosp Pharm; 1987 Jul; 44(7):1633-40. PubMed ID: 3631095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estimating treatment means in a mixed-effect ANOVA model for bioequivalence studies.
    Hsuan FC
    Biometrics; 1993 Sep; 49(3):703-13. PubMed ID: 8241367
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Statistical analysis of community-based studies -- presentation and comparison of possible solutions with reference to statistical meta-analytic methods].
    Twardella D; Bruckner T; Blettner M
    Gesundheitswesen; 2005 Jan; 67(1):48-55. PubMed ID: 15672306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A six-sigma approach to stability testing.
    De Vore K
    J Pharm Biomed Anal; 2008 Jun; 47(2):413-21. PubMed ID: 18262382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cumulative area pre-processing (CAP): a new treatment of UV data for the analysis of complex pharmaceutical mixtures.
    De Luca M; Ioele G; Ragno G
    J Pharm Biomed Anal; 2014 Mar; 90():45-51. PubMed ID: 24321517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simulation study of hierarchical regression.
    Witte JS; Greenland S
    Stat Med; 1996 Jun; 15(11):1161-70. PubMed ID: 8804145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic algorithm-optimized QSPR models for bioavailability, protein binding, and urinary excretion.
    Wang J; Krudy G; Xie XQ; Wu C; Holland G
    J Chem Inf Model; 2006; 46(6):2674-83. PubMed ID: 17125207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sensitivity analysis for m-estimates, tests, and confidence intervals in matched observational studies.
    Rosenbaum PR
    Biometrics; 2007 Jun; 63(2):456-64. PubMed ID: 17688498
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The concept of drug expiration dating.
    Wollish EG
    Bull Parenter Drug Assoc; 1969; 23(1):48-52. PubMed ID: 5765721
    [No Abstract]   [Full Text] [Related]  

  • 53. Estimating Shelf Life Through Tolerance Intervals Extended to Nonlinear Response Trends.
    Schwenke J; Stroup W; Quinlan M; Forenzo P
    AAPS PharmSciTech; 2023 Mar; 24(4):80. PubMed ID: 36944868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sample sizes for batch acceptance from single- and multistage designs using two-sided normal tolerance intervals with specified content.
    Hauck WW; Shaikh R
    J Biopharm Stat; 2001 Nov; 11(4):335-46. PubMed ID: 12018783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel QSPR study of normalized migration time for drugs in capillary electrophoresis by new descriptors: quantum chemical investigation.
    Riahi S; Beheshti A; Ganjali MR; Norouzi P
    Electrophoresis; 2008 Oct; 29(19):4027-35. PubMed ID: 18958895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Confidence intervals for random effects meta-analysis and robustness to publication bias.
    Henmi M; Copas JB
    Stat Med; 2010 Dec; 29(29):2969-83. PubMed ID: 20963748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deliquescence of pharmaceutical systems.
    Mauer LJ; Taylor LS
    Pharm Dev Technol; 2010 Dec; 15(6):582-94. PubMed ID: 19895256
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TRLFS: analysing spectra with an expectation-maximization (EM) algorithm.
    Steinborn A; Taut S; Brendler V; Geipel G; Flach B
    Spectrochim Acta A Mol Biomol Spectrosc; 2008 Dec; 71(4):1425-32. PubMed ID: 18555741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Random-effects models for serial observations with binary response.
    Stiratelli R; Laird N; Ware JH
    Biometrics; 1984 Dec; 40(4):961-71. PubMed ID: 6534418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rank regression in stability analysis.
    Chen YQ; Pong A; Xing B
    J Biopharm Stat; 2003 Aug; 13(3):463-79. PubMed ID: 12921394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.